Relay Therapeutics, Inc.

For the period ended Sep 30, 2025. Filed Nov 6, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 6, 2025

RLAY$19.94-2.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Loss

	Three Months Ended September 30,		Nine Months Ended September 30,
	2025	2024	2025	2024
Revenue:
License and other revenue	$—	$—	$8,355	$10,007
Total revenue	—	—	8,355	10,007
Operating expenses:
Research and development expenses	$68,262	$76,619	$205,968	$251,014
Change in fair value of contingent consideration liability	—	—	—	(13,206)
General and administrative expenses	12,129	19,750	44,495	59,688
Total operating expenses	80,391	96,369	250,463	297,496
Loss from operations	(80,391)	(96,369)	(242,108)	(287,489)
Other income:
Interest income	6,407	8,274	21,325	25,772
Other (expense) income	(165)	(10)	(806)	13
Total other income, net	6,242	8,264	20,519	25,785
Net loss	$(74,149)	$(88,105)	$(221,589)	$(261,704)
Net loss per share, basic and diluted	$(0.43)	$(0.63)	$(1.30)	$(1.94)
Weighted average shares of common stock, basic and diluted	172,389,209	140,229,056	170,973,889	134,651,728
Other comprehensive income (loss):
Unrealized holding gain	656	3,849	1,484	2,705
Total other comprehensive income	656	3,849	1,484	2,705
Total comprehensive loss	$(73,493)	$(84,256)	$(220,105)	$(258,999)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.